Distribution · Southeast Asia · Announced 5 Nov 2026
Novo Nordisk → Abbott
Novo Nordisk and Abbott expanded their partnership so Abbott will market and distribute Plosbrio, a second brand of Novo's semaglutide (Ozempic), in Singapore and other Asia Pacific markets; terms were not disclosed.
Parties: Novo Nordisk (Denmark) → Abbott (United States)
- Deal type
- Distribution
- Value
- Undisclosed
- Territory
- Singapore first, then other Asia Pacific markets (not yet named), subject to local approvals
- Therapeutic area
- Metabolic / Diabetes
- Asset
- Plosbrio (semaglutide)
- Announced
- 5 Nov 2026
Our analysis
Why this matters
On 5 November 2026, Abbott and Novo Nordisk announced an expanded partnership under which Abbott will commercialise Plosbrio, a second brand of Novo's semaglutide injection (Ozempic), in Singapore and other Asia Pacific countries. Novo develops and manufactures the product; Abbott promotes and distributes it. Plosbrio is indicated, alongside diet and exercise, for glycaemic control in adults with type 2 diabetes, and to reduce cardiovascular and kidney risk in adults with type 2 diabetes and established heart or kidney disease. The companies stress it is not a weight-loss product. No financial terms or market-by-market launch dates were disclosed; availability depends on local registration.
The deal follows the same model Abbott uses in India, where it sells Extensior, another second brand of semaglutide, under a deal announced in February 2026. The release cites IDF estimates of more than 107 million adults with diabetes in Southeast Asia, projected to reach about 185 million by 2050.
The full analysis is free to read with a work email on this page.